English

• 18 Jun, 2026
  Spago Nanomedical announces outcome of rights issue
• 10 Jun, 2026
  Bulletin from the 2026 Annual General Meeting of Spago Nanomedical AB
• 3 Jun, 2026
  The subscription period in Spago Nanomedical’s rights issue begins today
• 2 Jun, 2026
  Spago Nanomedical publishes information document in connection with forthcoming rights issue
• 22 May, 2026
  Spago Nanomedical resolves on a rights issue of approximately SEK 16 million
• 19 May, 2026
  Spago Nanomedical publishes the annual report for 2025
• 18 May, 2026
  Spago Nanomedical presents Tumorad® clinical data at the international ANZSNM 2026 conference
• 11 May, 2026
  NOTICE TO ANNUAL GENERAL MEETING OF SPAGO NANOMEDICAL AB (PUBL)
• 7 May, 2026
  Spago Nanomedical interim report January-March 2026
• 6 May, 2026
  Spago Nanomedical’s phase I/IIa study Tumorad-01 meets a primary endpoint and provides further visible tumor uptake